
|Videos|June 22, 2021
Pharmacist Medication Insights: Xembify for Primary Humoral Immunodeficiency Disease
Author(s)Saro Arakelians, PharmD
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Advertisement
Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.
Xembify is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
2
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
3
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
4
McKesson ideaShare 2026: How AI and Automation Are Reshaping the Dispensing Experience
5





















































































































